← board
CELU
distress 4/10 · elevated risk$0.78-4%today-81% from 52w high
Revenue
$27M
Liquidity
$9M
Runway
0.7 yrs
Shares 1y
+8%
Price & events
-38.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.7%
1D
+0.0%
1W
+2.9%
1M
-33.3%
3M
-38.8%
6M
-79.1%
1Y
-73.3%
2Y
-99.2%
5Y
-99.3%
All
Overview
- Market Cap
- $22.58M
- Volume
- 21.50K
- 52 Week Range
- $0.60 – $4.15
- Total Shares
- 28.95M
- Float Shares
- 18.87M
- Short %
- 6.21%
- % Held by Insiders
- 37.18%
- % Held by Institutions
- 12.77%
- RVOL
- 0.17x
- Beta
- 0.54
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-04-21partnershipClosed asset purchase and exclusive license agreement with NexGel for biomaterials portfolioSEC 8-K
- 2026-03-06partnershipEntered into asset purchase and exclusive license agreement with NexGel for biomaterials portfolio; up to $35M in upfront and milestone paymentsSEC 8-K
- 2025-12-01warning letterInterfyl · FDA warning letter regarding use of outcome-based claims and metabolic activity in marketing material for InterfylSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 28,945,961 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-09-09WBB SecuritiesHold → Buy
- 2025-08-18WBB SecuritiesSpeculative Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.